2020
Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients
Gaston DC, Malinis M, Osborn R, Peaper DR, Landry M, Juthani-Mehta M, Azar MM. Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients. American Journal Of Transplantation 2020, 21: 1304-1311. PMID: 33043603, PMCID: PMC7675520, DOI: 10.1111/ajt.16357.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsClinical implicationsCycle threshold valuesSOT patientsTransplant recipientsSymptom onsetYale New Haven Health SystemUpper respiratory tract samplesSARS-CoV-2 viral RNASARS-CoV-2 viral dynamicsAdult SOT recipientsRetrospective chart reviewRespiratory tract samplesSARS-CoV-2 cycle threshold valuesInfection prevention measuresCOVID-19 severityViral RNAHigher clinical acuityPrimary diagnostic testRT-PCR assaysSOT recipientsChart reviewViral loadAdmission severityOutcomes of Patients With Hospital-Acquired Influenza
Campbell M, James A, Fairweather I, Rivera-Vinas J, Kaslow R, Landry M, Peaper D, Martinello R. Outcomes of Patients With Hospital-Acquired Influenza. Infection Control And Hospital Epidemiology 2020, 41: s340-s340. DOI: 10.1017/ice.2020.951.Peer-Reviewed Original ResearchEscalation of careIntensive care unitCare unitLaboratory-proven influenzaOutcomes of patientsRetrospective cohort studyCommunity-based populationPediatric teaching hospitalLength of stayOnset of signsDiagnosis of pneumoniaMedical record informationDirect fluorescent antibodyNoninvasive ventilationChart reviewCohort studyInpatient morbidityMedian durationPatient demographicsAntiviral treatmentClinical courseRadiographic evidenceAntiviral administrationInfluenza infectionSupplemental oxygenHigh Agreement Between an Ultrasensitive Clostridioides difficile Toxin Assay and a C. difficile Laboratory Algorithm Utilizing GDH-and-Toxin Enzyme Immunoassays and Cytotoxin Testing
Landry ML, Topal JE, Estis J, Katzenbach P, Nolan N, Sandlund J. High Agreement Between an Ultrasensitive Clostridioides difficile Toxin Assay and a C. difficile Laboratory Algorithm Utilizing GDH-and-Toxin Enzyme Immunoassays and Cytotoxin Testing. Journal Of Clinical Microbiology 2020, 58: 10.1128/jcm.01629-19. PMID: 31776192, PMCID: PMC6989068, DOI: 10.1128/jcm.01629-19.Peer-Reviewed Original ResearchConceptsToxin enzyme immunoassayToxin A/BCell cytotoxicity neutralization assayEnzyme immunoassayStool samplesDifficile toxin assaysProspective clinical studyCytotoxicity neutralization assayCare algorithmChart reviewClinical studiesToxin ACytotoxin testingNeutralization assaysToxin assaysNegative agreementDiscordant samplesLaboratory algorithmTesting algorithmHigh agreementInfection diagnosticsGlutamate dehydrogenasePositive agreementImmunoassayAssays
2013
Comparison of Simplexa Universal Direct PCR with Cytotoxicity Assay for Diagnosis of Clostridium difficile Infection: Performance, Cost, and Correlation with Disease
Landry ML, Ferguson D, Topal J. Comparison of Simplexa Universal Direct PCR with Cytotoxicity Assay for Diagnosis of Clostridium difficile Infection: Performance, Cost, and Correlation with Disease. Journal Of Clinical Microbiology 2013, 52: 275-280. PMID: 24226924, PMCID: PMC3911468, DOI: 10.1128/jcm.02545-13.Peer-Reviewed Original ResearchConceptsAntigen-negative samplesGDH antigenToxigenic C. difficileC. difficileGDH-positive samplesClostridium difficile infectionGlutamate dehydrogenase antigenToxin B geneSemisolid stoolsC. difficile toxin B geneDifficile testingChart reviewNosocomial transmissionDifficile infectionDifficile diseaseReal-time PCRClinical consequencesMerit further studyRapid molecular diagnosisDifficile bacteriaAntigenPatientsDehydrogenase antigenCost avoidanceCytotoxicity assays
2009
Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use
Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ. Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use. PLOS ONE 2009, 4: e6079. PMID: 19562031, PMCID: PMC2698118, DOI: 10.1371/journal.pone.0006079.Peer-Reviewed Original ResearchConceptsAntiretroviral treatment historyDrug-resistant mutationsVirologic failureAntiretroviral useDrug-resistant variantsTreatment historyOverall burdenGenotypic resistanceHIV drug-resistant mutationsHIV drug-resistant variantsStanford HIV database algorithmDrug-resistant viral variantsSubsequent antiretroviral regimensTreatment-experienced patientsConventional genotypingPrior treatment historyUltra-deep pyrosequencingSanger sequencingAntiretroviral regimensMore antiretroviralsChart reviewAntiretroviral drugsUltra-deep sequencingClinical implicationsViral variants